A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Azelastine and Fluticasone Azelastine

Azelastine and Fluticasone vs Azelastine — $131.8M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Histamine-1 Receptor Antagonist
Azelastine and Fluticasone
Brand: DYMISTA
First FDA approval:
Histamine-1 Receptor Antagonist
Azelastine
Brand: Azelastine Hydrochloride
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$2.26Per unit
$0.286Per unit
Average NADACAcross all dosage forms and strengths
$3.98Up to $9.15
$0.552Up to $0.883
Generic manufacturersActive ANDA holders — FDA Orange Book
00 total ANDAs filed
1011 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
Full year
$131.8MFull year
Part D claims (CY24)Total fills, all strengths
— beneficiaries
5.1M2.4M beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
Per claim, all NDCs
$26Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
0Zero PA friction
0Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
3Limited friction
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
DiscontinuedSee drug profile
NoneClear
Generic availableFDA Orange Book
NoBrand-only
Yes10 manufacturers